Fei Ling Feng

Publications (3)2.82 Total impact

• Article: Role of radical resection in patients with gallbladder carcinoma and jaundice.

  Fei-ling Feng, Chen Liu, Bin Li, Bai-he Zhang, Xiao-qing Jiang
  [show abstract] [hide abstract]
  ABSTRACT: Gallbladder carcinoma (GBC) is a commonly-seen malignancy of the biliary tract characterized by difficult early diagnosis, rapid growth, early metastasis, and poor prognosis. Nearly half of GBC patients also have jaundice, which is a mark of the advanced stage of GBC. The role of radical resection in patients of gallbladder carcinoma with jaundice is still a matter of uncertainty, which we attempted to clarify in this study. Totally, 251 GBC patients who received treatment at the Eastern Hepatobiliary Surgery Hospital (EHBH) from December 2002 to January 2010 were recruited into this study. We divided them into group A (jaundice group, n=117) and group B (non-jaundice group, n=134). Clinical records and follow-up data were collected and retrospectively analyzed in both groups. Compared with group A, patients in group B had a longer median survival time ((6.0±0.5) months vs. (15.0±2.6) months, P<0.01). Even in patients with stage III or stage IV GBC, the median survival time in patients without jaundice (n=111), was still longer than that in patients with jaundice (n=116) (P<0.01). The radical resection rate was lower in group A patients than in group B patients with stage III or stage IV GBC; 31.9% vs. 63.1%. However, the median survival time of patients undergoing radical resection did not show a statistical difference between jaundice patients and non-jaundice patients; (12.0±4.3) months vs. (18.0±3.0) months (P>0.05). GBC with jaundice usually implies advanced stage disease and a poor prognosis for the patients. However, our findings indicate that as long as the patient's condition allows, radical resection is still feasible for GBC patients with jaundice, and may achieve a prognosis close to those GBC patients without jaundice.
  Chinese medical journal 03/2012; 125(5):752-6. · 0.86 Impact Factor
• Article: Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.

  Wei-feng TAN, Zhi-quan Qiu, Yong YU, Rong-zheng RAN, Bing YI, Wan-yee LAU, Chen LIU, Ying-he QIU, Fei-ling FENG, Jing-Han WANG, Pei-ning YAN, Bai-he ZHANG, Meng-chao WU, Xiang-ji LUO, Xiao-qing JIANG
  [show abstract] [hide abstract]
  ABSTRACT: to determine the efficacy and toxicities of sorafenib in the treatment of patients with multiple recurrences of hepatocellular carcinoma (HCC) after liver transplantation in a Chinese population. twenty patients with multiple recurrences of HCC after liver transplantation were retrospectively studied. They received either transarterial chemoembolization (TACE) or TACE combined with sorafenib. the median survival times (MST) after multiple recurrences was 14 months (TACE+sorafenib group) and 6 months (TACE only group). The difference was significant in MST between the two groups (P=0.005). The TACE + sorafenib group had more stable disease (SD) patients than the TACE group. The most frequent adverse events of sorafenib were hand-foot skin reaction and diarrhea. In the univariate analysis, preoperative bilirubin and CHILD grade are found to be significantly associated with tumor-free survival time, the survival time after multiple recurrences and overall survival time. TACE+sorafenib group showed a better outcome than single TACE treatment group. In the multivariate COX regression modeling, the preoperative high CHILD grade was found to be a risk factor of tumor-free survival time. In addition, the preoperative high bilirubin grade was also found to be a risk factor of survival time after recurrence and overall survival time. Furthermore, survival time after recurrence and overall survival time were also associated with therapeutic schedule, which was indicated by the GROUP. Treatment with TACE and sorafenib is worthy of further study and may have more extensive application prospects.
  Acta Pharmacologica Sinica 12/2010; 31(12):1643-8. · 1.95 Impact Factor
• Article: Clinical characteristics of acute pancreatitis patients with elevated serum triglyceride concentration.

  Chong Yi Jiang, Tian Quan Han, Fei Ling Feng, Lei Kong, Xing Xing Cai, Sheng Dao Zhang
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate the clinical characteristics of acute pancreatitis (AP) patients with elevated serum triglyceride (TG) concentration. Ninety-nine cases of AP admitted from January 2000 to January 2002 were analyzed: 28 cases comprised the TG-elevated group (serum TG >1.7 mmol/L) and 71 cases were the TG-normal group (serum TG </=1.7 mmol/L). The AP patients with elevated serum TG accounted for 11.3% (9/80) of all AP cases during the study period. Pulmonary, cardiovascular and renal dysfunction within 72 h of onset of AP were all higher in the TG-elevated group than in the group with normal TG (25.0% vs 1.4%; 17.9% vs 1.4%; 14.3% vs 1.4%, respectively; P < 0.05). The incidence of pancreatic pseudocyst was 53.6% and 4.2%, respectively, in the group with elevated TG and in the group with normal TG (P < 0.05). Patients with AP and elevated serum TG concentration have organ dysfunction at an earlier stage and increased local complications. Non-surgical therapy was common for the majority of these patients.
  Chinese Journal of Digestive Diseases 02/2005; 6(1):43-6.